TREATMENT OF PRIMARY PLASMA CELL LEUKAEMIA

• Main Author: Peter Černelč
• Format: Article
• Language: English
• Published: Slovenian Medical Association 2003-04-01
• Series: Zdravniški Vestnik
• Subjects: primary plasma cell leukaemia; treatment; melphalan; VAD; C-VAMP; blood stem cell transplantation; interferon alpha
• Online Access: http://vestnik.szd.si/index.php/ZdravVest/article/view/1818
• ISSN: 1318-0347; 1581-0224

<p>Background. The author describes long-term survival in 3 patients with primary plasma cell leukaemia (PL) after different therapeutic regimen and maintenance treatment with interferon alpha (INF).</p><p>Patients and treatment. In a 52-year-old male patient, a partial remission of PL was achieved after 6 months of treatment with melphalan and prednisone. The patient did not consent to stem cell transplantation (SCT). An 86-year-old female patient with PL achieved a complete remission after 6 months of treatment with vincristine, doxorubicin and dexamethasone. A 31-year-old male patient experienced a complete remission of PL after 6 months of treatment with cyclophosphamide, vincristine, doxorubicin, methilprednisone, followed by autologous SCT. All three patients were placed on maintenance therapy with INF-2b (Intron A) 3 × 106 IU given subcutaneously on two days per week. In the 52-year-old man, the remission lasted 9 months and in the woman 23 months, whereupon they developed a relapse with signs of disseminated plasmacytoma. In both patients the former chemotherapy was applied again, resulting in a slight improvement. The man died 37 months and the woman 43 months after the diagnosis of PL, while the youngest patient has been in complete remission for 82 months.</p><p>Conclusions. Long remission achieved in our patients confirmed the favourable effect of INF in terms of prolongation of the remission duration in this patients. The effect of maintenance treatment with INF is usually directly dependent on the degree of remission induced by different therapeutic regimen.<br /><br /></p>